Syndax Pharmaceuticals, Inc. Deferred Tax Assets, Deferred Income
Syndax Pharmaceuticals, Inc. (SNDX) had Deferred Tax Assets, Deferred Income of $2.99 million as of 2020-12-31, per its 10-K filed 2022-03-01.
Discontinued › Notes › Income Taxes › Deferred Tax Assets, Net › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsDeferredIncome · last filed 2022-03-01
- 2020-12-31: Deferred Tax Assets, Deferred Income $2.99M.
- 2019-12-31: Deferred Tax Assets, Deferred Income $3.33M.
- 2018-12-31: Deferred Tax Assets, Deferred Income $3.69M.
- 2017-12-31: Deferred Tax Assets, Deferred Income $3.24M.
| Period end | Deferred Tax Assets, Deferred Income |
|---|---|
| 2020-12-31 | $2.99M 10-K · filed 2022-03-01 |
| 2019-12-31 | $3.33M 10-K · filed 2021-03-12 |
| 2018-12-31 | $3.69M 10-K · filed 2020-03-05 |
| 2017-12-31 | $3.24M 10-K · filed 2019-03-07 |
| 2016-12-31 | $5.42M 10-K · filed 2018-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |